Maribavir is an oral benzimidazole riboside for treatment of post-transplant cytomegalovirus (CMV) infection/disease that is refractory to prior antiviral treatment (with or without resistance). Through competitive inhibition of adenosine triphosphate, maribavir prevents the phosphorylation actions of UL97 to inhibit CMV DNA replication, encapsidation, and nuclear egress. Maribavir is active against CMV strains with viral DNA polymerase mutations that confer resistance to other CMV antivirals. After oral administration, maribavir is rapidly and highly absorbed (fraction absorbed >90%). The approved dose of 400 mg twice daily (BID) achieves a steady-state area under the curve (AUC) per dosing interval of 128 h*μg/mL and trough concentration of 4.90 μg/mL (13.0 μM). Maribavir is highly bound to human plasma proteins (98%) with a small apparent volume of distribution at 27.3 L. Maribavir is primarily cleared by hepatic CYP3A4 metabolism; its major metabolite, VP44669 (pharmacologically inactive), is excreted in the urine and feces. There is no clinically relevant impact on maribavir pharmacokinetics by age, sex, race/ethnicity, body weight, transplant type, or hepatic/renal impairment status. In Phase 2 dose-ranging studies, maribavir showed similar rates of CMV viral clearance across 400, 800, or 1200 mg BID groups, ranging 62.5-70% in Study 202 (NCT01611974) and 74-83% in Study 203 (EudraCT 2010-024247-32). In the Phase 3 SOLSTICE trial (NCT02931539), maribavir 400 mg BID demonstrated superior CMV viremia clearance at week 8 versus investigator-assigned treatments with lower treatment discontinuation rates. Dysgeusia, nausea, vomiting and diarrhea were commonly experienced adverse events among patients treated with maribavir in clinical trials.
This article is protected by copyright. All rights reserved.